Plain-English translation of NCT06318598 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study designed to help researchers understand why ALS (amyotrophic lateral sclerosis) affects different people in different ways. Instead of testing a new medication, researchers will collect genetic information and biological samples from ALS patients to identify distinct subtypes of the disease. This knowledge could eventually help doctors personalize treatment plans.
ALS looks and progresses differently in each patient, and doctors don't yet understand why some people are affected in one way while others experience the disease very differently. By studying genetic and biological markers, researchers hope to identify which patients belong to which disease subgroups—information that could eventually lead to more targeted and effective treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the study center for a series of evaluations including a neurological exam, nerve and muscle tests, thinking and memory assessments, and genetic testing. The researchers will also collect small samples of blood and cerebrospinal fluid (from a spinal tap) to measure biological markers. The study does not involve taking any new medication—it is focused on gathering information to help researchers better understand ALS.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Italy
Collaborators
A.O.U. Città della Salute e della Scienza, Ospedale San Raffaele
Enrollment target
~200 participants
Started
April 2023
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nicola Ticozzi, MD, PhD
Istituto Auxologico Italiano
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.